Safety Profiles of Ruxolitinib and Fedratinib in Myelofibrosis
Prithviraj Bose, MD, discusses differences in the safety profiles of ruxolitinib and fedratinib in the treatment of myelofibrosis.
Prithviraj Bose, MD, associate professor, The University of Texas MD Anderson Cancer Center, discusses differences in the safety profiles of ruxolitinib (Jakafi) and fedratinib (Inrebic) in the treatment of myelofibrosis.
Bose believes ruxolitinib and fedratinib are similar in terms of efficacy and toxicity. Looking at ruxolitinib in the COMFORT trial and fedratinib in the JAKARTA trial, the rate of spleen volume reduction, total symptom score reduction and the incidence of the main adverse events, including anemia, and thrombocytopenia, are comparable, according to Bose.
Savona Discusses First-Line JAK Inhibition for Patients With Myelofibrosis at Risk of Anemia
April 17th 2024During a Case-Based Roundtable® event, Michael Savona, MD, and participants discussed the case of a patient with myelofibrosis and moderate anemia receiving JAK inhibitor therapy.
Read More
PTCy Offers New Hope for Mismatched Stem Cell Transplants in Leukemia, MDS
April 13th 2024Jeff Auletta, MD, discussed how PTCy-based graft-vs-host disease prophylaxis offers a promising approach for expanding access to successful cell transplantation regardless of donor match or patient ethnicity.
Read More
